Cover image for GLP-1 Pipeline Update: February 2025 Quarterly view of the GLP-1 pipeline and anticipated indications Prime Therapeutics /glp-1-pipeline-update-february-2025 Prime Therapeutics’...

Cover image for GLP-1 Pipeline Update: May 2025 Quarterly view of the GLP-1 pipeline and anticipated indications Prime Therapeutics /glp-1-pipeline-update-may-2025 Prime Therapeutics’ GLP-1...

Cover image Quarterly view of the GLP-1 pipeline and anticipated indications. Prime Therapeutics /glp-1-pipeline-update-november-2024 Prime Therapeutics’ GLP-1 Pipeline Update focuses on the...

Maryam Tabatabai, PharmD, vice president of clinical information, and Carole Kerzic, RPh, drug information pharmacist, share more about glucagon-like peptide-1 (GLP-1) receptor agonists in the drug...

publications GLP-1 Pipeline Update: November 2024 Quarterly view of the GLP-1 pipeline and anticipated indications November 21, 2024 Editorial team Maryam Tabatabai, PharmD Editor-In-Chief Vice...

publications GLP-1 Pipeline Update: February 2025 Quarterly view of the GLP-1 pipeline and anticipated indications February 26, 2025 Editorial team Maryam Tabatabai, PharmD Editor-In-Chief...

publications GLP-1 Pipeline Update: May 2025 Quarterly view of the GLP-1 pipeline and anticipated indications May 27, 2025 Editorial team Maryam Tabatabai, PharmD Editor-In-Chief Associate Vice...

Leading GLP-1 persistence, adherence and clinical outcomes research helps inform health plans and members

cover image for the 2025 Spring Prime Therapeutics Report Autoimmune management: Updates and challenges Prime Therapeutics /spring-2025-prime-therapeutics-report The Prime Therapeutics Report is...

publications Spring 2025 Prime Therapeutics Report March 21, 2025 The Prime Therapeutics Report is your source for innovative managed care strategies, trends and updates. Our cover story (Page...

publications Quarterly Drug Pipeline: April 2025 Clinical insights and competitive intelligence on anticipated drugs in development April 25, 2025 Editor-in-chief's message Welcome to the Prime...

New resource page offers the latest GLP-1 insights, research and perspectives

New report details the latest on GLP-1s

Following real-world analysis of GLP-1 drugs for weight loss, Prime/Magellan Rx releases new video about GLP-1 research

Jessica Johnson, clinical consultant at Prime Therapeutics, shares more about common GLP-1 fraud schemes

Real-world study of GLP-1 patients continues to deliver leading insights

David Lassen, vice president of pharmacy clinical services, and Marci Chodroff, vice president and medical director at Prime Therapeutics, share more about the latest GLP-1 insights from ongoing...

Among the key findings from the study — among 4,066 members, Prime/MRx found 1 in 3 stayed on their GLP-1 and 27% took their medication as intended

Jessica Johnson, clinical consultant at Prime's Special Investigations Unit, shares how to identify fake GLP-1s

Ben Urick, senior director of health outcomes, and Landon Marshall, health outcomes research principal, share more about their educational session and research poster on GLP-1s

BioSpace: While drug developers work to mitigate the side effects associated with GLP-1–based obesity drugs, recent studies reveal that myriad variables are causing patients to stop treatment

Real-world, integrated data follows-up on previous insights, analytics.

Develop a holistic GLP-1 strategy An evidence-based approach to GLP-1 drugs helps you implement custom strategies that promote clinically appropriate use and consider affordability, long-term value...

Jessica Johnson, clinical consultant, shares how the Special Investigations Unit at Prime helps identify cases of fraud

Cover image for Quarterly Drug Pipeline: January 2025 Updates on promising therapies in development, focusing on drugs nearing FDA approval Prime Therapeutics /quarterly-drug-pipeline-january-2025...

cover image for Quarterly Drug Pipeline: October 2024 Quarterly Drug Pipeline: October 2024 Prime Therapeutics /quarterly-drug-pipeline-october-2024 Prime Therapeutics’ Quarterly Drug Pipeline...

Managed Healthcare Executive: A Prime Therapeutics analysis of real-world data has found that medical costs for patients taking GLP-1 drugs for obesity had increased by about $1,338 per member,...

Urick, senior principal health outcomes researcher, shares more about his Spotlight Session at the Academy of Managed Care Pharmacy (AMCP)’s Annual Meeting

Cover image for Quarterly Drug Pipeline: April 2025 Clinical insights and competitive intelligence on anticipated drugs in development Prime Therapeutics /quarterly-drug-pipeline-april-2025 Prime...

In this second of a two-part episode of the Pharmacy Friends podcast, industry experts discuss clinical evidence, drug information and appropriate patient selection for GLP-1 use

Event on Sept. 11 in Washington D.C. will feature the latest information on using GLP-1s to tackle the obesity epidemic.

What to expect at Academy of Managed Care Pharmacy (AMCP) Nexus 2023

Pat Gleason, assistant vice president, health outcomes, and David Eckwright, senior director, clinical project and program management, share an overview of Prime’s data and insights slated for this...

Prime to present seven studies and receive the 2024 JMCP Award for Excellence

GLP-1 year two cost effectiveness study abstract

The event emphasizes additional measures for obesity therapy.

Live updates from AMCP Annual Meeting

Forbes

publications Quarterly Drug Pipeline: October 2024 Clinical insights and competitive intelligence on anticipated drugs in development October 31, 2024 Editor-in-chief's message Welcome to the Prime...

Pharmacy Practice News, originally published by Specialty Pharmacy Continuum